The global pharma industry experienced an 11% rise in social media posts on regenerative medicine in Q1 2023 compared with the previous quarter, with the highest share accounted for Pfizer, according to GlobalData’s analysis of social media posts. GlobalData’s Regenerative Medicine in Medical thematic intelligence report provides an overview of the current landscape, including healthcare, technology, regulatory, macroeconomic trends, and key players. Buy the report here.
Smarter leaders trust GlobalData
Notably, Covid-19 was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions ahead of orphan designated drugs and innovation, according to GlobalData.
Of the 50 leading companies in the pharma industry, Pfizer had the most mentions of regenerative medicine in Q1 2023. GlobalData identified 2,048 regenerative medicine-related posts in the industry's social media activity - 0.13% of all posts - and an increase of 11% in Q1 2023 compared with Q4 2022.
For further understanding of GlobalData's Regenerative Medicine in Medical - Thematic Research buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
